Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam for Intravenous Sedation in Paediatric Patients
NCT04851717Phase 3Active, not recruiting
- Sponsor
- Acacia Pharma Group Plc
- Start
- Nov 2021
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of remimazolam in Procedural sedation (PS), sponsored by Acacia Pharma Group Plc. Primary endpoint: Success of the procedure at 2 hours. Started Nov 2021; status: active, not recruiting.
02
Drugs
remimazolam
03
Conditions
Procedural sedation (PS)
Beyond the preview
Go deeper on NCT04851717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04851717.